News | Structural Heart | September 26, 2022

Medtronic Announces FDA Approval of Next-Gen TAVR System for Treatment of Symptomatic Severe Aortic Stenosis

Evolut FX TAVR System Adds Innovative Features to Enhance Ease-of-Use and Predictable Valve Deployment

Evolut FX TAVR System Adds Innovative Features to Enhance Ease-of-Use and Predictable Valve Deployment

September 26, 2022 — Medtronic plc, a global leader in medical technology, announced U.S. Food and Drug Administration (FDA) approval of its newest-generation, self-expanding transcatheter aortic valve replacement (TAVR) system, the Evolut FX TAVR system. Designed to enhance ease-of-use and provide greater precision and control throughout the procedure, the Evolut FX system maintains the industry-leading hemodynamic (blood flow) and durability benefits of the Evolut platform, while bringing product and procedure innovation for patients with symptomatic severe aortic stenosis

The Evolut FX system incorporates the same supra-annular valve design that has shown hemodynamic performance superior to surgical aortic valve replacement (SAVR) across large-scale, randomized clinical trials. The fourth-generation Evolut technology is equipped with gold markers built into the frame to provide implanters with direct visualization of depth and valve leaflet location during implant. In addition, the Evolut FX system incorporates a redesigned catheter tip for a smoother insertion profile, a more flexible delivery system that allows for 360-degree freedom of motion, with a stable, predictable deployment. Like its predecessor (Evolut PRO+), the newest system includes four valve sizes for the largest indicated patient treatment range and the lowest delivery profile currently on the market. 

"The self-expanding, supra-annular Evolut platform has evolved considerably over time and has brought heart teams innovative features like recapturability, an expanded size matrix, and advanced valve sealing to help minimize paravalvular leak. Today, the Evolut FX system further refines a trusted platform with key product and procedural enhancements that make the self-expanding system easier to use with enhanced visualization capabilities for orientation and depth," said Jeffrey Popma, M.D., vice president and chief medical officer for the Coronary & Renal Denervation business and the Structural Heart & Aortic business, which are part of the Cardiovascular Portfolio at Medtronic. 

Severe aortic stenosis occurs when the aortic valve leaflets become stiff and thickened and have difficulty opening and closing, making the heart work harder to pump blood to the rest of the body. Severe aortic stenosis often reduces a patient's quality of life and limits their daily activities. If left untreated, patients with symptomatic severe aortic stenosis can die from heart failure in as little as two years. 

The Evolut TAVR platform (including the Evolut R, Evolut PRO, Evolut PRO+, and Evolut FX) is indicated for symptomatic severe aortic stenosis patients across all risk categories (extreme, high, intermediate and low) in the U.S. Limited commercial release is planned for the fall with a full launch anticipated in early 2022. 

In collaboration with leading clinicians, researchers and scientists worldwide, Medtronic offers the broadest range of innovative medical technology for the interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias. The company strives to offer products and services that deliver clinical and economic value to healthcare consumers and providers around the world. 

For more information: www.medtronic.com 

Find more TCT22 coverage here


Related Content

News | Interventional Radiology

August 11, 2022 — Bracco Imaging S.p.A. has announced the renewal of the “Bracco Fellowships” initiative, in partnership ...

Home August 11, 2022
Home
News | Interventional Radiology

May 18, 2022 — XACT Robotics, developer of the world’s first and only comprehensive robotic system for interventional ...

Home May 18, 2022
Home
News | Interventional Radiology

April 27, 2022 – Omega Medical Imaging has announced the release of the revolutionary Soteria.AI. Designed specifically ...

Home April 27, 2022
Home
News | Interventional Radiology

March 18, 2021 — The U.S. Food and Drug Administration (FDA) has cleared Boston Scientific's TheraSphere Y-90 Glass ...

Home March 18, 2021
Home
Feature | Interventional Radiology | By Katie Caron

A new year — and decade — offers the opportunity to reflect on the advancements and challenges of years gone by and ...

Home April 03, 2020
Home
News | Interventional Radiology | Melinda Taschetta-Millane

March 9, 2020 — As the novel coronavirus (COVID-19) slowly spreads across the globe, more industry conferences are ...

Home March 09, 2020
Home
News | Interventional Radiology

February 11, 2020 — An ahead-of-print article in the April issue of the American Journal of Roentgenology (AJR) ...

Home February 11, 2020
Home
News | Interventional Radiology

February 4, 2020 — For some patients, kidney cancer can be effectively treated without surgery, according to the Society ...

Home February 04, 2020
Home
Videos | Interventional Radiology

Scott Schwartz, M.D., interventional radiologist and program director for IR residencies and the vascular and ...

Home September 10, 2019
Home
News | Interventional Radiology

April 10, 2019 —Smart speakers customarily used in your living room can act as an aid to physicians in hospital ...

Home April 10, 2019
Home
Subscribe Now